Credit Acceptance Corp. (MI) (CACC) Drops 5.03% on January 15

Equities Staff |

Credit Acceptance Corp. (MI) (CACC) was one of the Russell 2000's biggest losers for Friday January 15 as the stock slid 5.03% to $176.59, a loss of $-9.36 per share. Starting at an opening price of $181.00 a share, the stock traded between $175.51 and $182.46 over the course of the trading day. Volume was 223,262 shares over 2,509 trades, against an average daily volume of 171,089 shares and a total float of 20.6 million.

The losses send Credit Acceptance Corp. (MI) down to a market cap of $3.64 billion. In the last year, Credit Acceptance Corp. (MI) has traded between $277.98 and $134.34, and its 50-day SMA is currently $200.36 and 200-day SMA is $214.37.

The stock has a P/E Ratio of 13.4.

Credit Acceptance Corp is a financing company. The Company offers automobile dealers financing programs that enable them to sell vehicles to consumers regardless of their credit history.

Credit Acceptance Corp. (MI) is based out of Southfield, MI and has some 1,303 employees. Its CEO is Brett A. Roberts.

For a complete fundamental analysis analysis of Credit Acceptance Corp. (MI), check out’s Stock Valuation Analysis report for CACC. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…